viral hpv protein Search Results


recombinant viral hpv e6 protein, cf  (Bio-Techne corporation)
94
Bio-Techne corporation recombinant viral hpv e6 protein, cf
Recombinant Viral Hpv E6 Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/viral+hpv+protein/Recombinant+Viral+HPV+E6+Protein%2C+CF/bio-techne+corporation___ap-120
Average 94 stars, based on 1 article reviews
recombinant viral hpv e6 protein, cf - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
e6 protein  (R&D Systems)
93
R&D Systems e6 protein
a. HPV-16 therapeutic vaccine clinical trial design. Patients received vaccines targeting <t>E6</t> and E7 proteins at Week 0, 4, and 8. PBMCs were collected pre-vaccination, at Week 10, and at Week 15 post-series completion. b. left, UMAP clustering of CD4+ T cells from PBMCs of HPV16+ patients with persistent precancerous lesions. right, HPV16-specific CD4+ T cells identified by SCT-dextramers. c. Highlighting of H1-H5 TCR clones among HPV16-specific CD4+ T cells. d. Expression of signature gene markers for defining phenotype clusters. Mean expression levels were normalized across groups. e. Engineering of primary CD4+ T cells with HPV-specific TCRs. CD4+ T cells were enriched from haplotype-matched PBMCs, endogenous TCRs were knocked out using CRISPR, and HPV TCRs were transduced via lentivirus. f. Validation of TCR specificity by tetramer binding (n=3) . g. Transduction efficiency of HPV-specific CD4 TCRs into primary CD4+ versus CD8+ T cells. h. Alanine scanning to identify key TCR recognition motifs. H2- and H5-TCR-transduced CD4+ T cells were cocultured with DR1+ K562 cells pulsed with alanine-substituted 9-mer core peptides (A1-A9) across 0.001 – 1 μM. IFNγ secretion was measured (OD 450 ). i. Cross-reactivity analysis against human self-antigens. H2- and H5-TCR-transduced T cells were co-cultured with LCLs pulsed with peptides identified from BLAST search and motif scans. H2 TCR used a single 1 µM dose; H5 TCR was dose titrated at 1, 2, and 10 µM. j. Alloreactivity screen. H2- and H5-TCR-transduced CD4+ T cells were tested against 41 LCL lines representing 92 distinct class II HLA <t>alleles.</t> <t>DRB1*01:01-positive</t> LCLs ( n=4 ) pulsed with E6 91-107 or E6 129-142 served as positive controls. Alloreactivity of H5 to HLA-DRB1*13:05-positive LCLs is marked with orange arrows. k. Confirmation of H2 TCR reactivity to naturally processed E6 antigen. DRB1*01:01+ LCL (GM17281B) was titrated with full-length E6 protein (0-10 μg/mL), co-cultured with H2-TCR-transduced CD4+ T cells, and evaluated for IFNγ secretion. A DRB1*01:01-LCL (GM12244A) served as a negative control.
E6 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/viral+hpv+protein/Recombinant+Viral+HPV+E6+Protein%2C+CF/bio_rxiv__2025__04__21__649828-291-7-9
Average 93 stars, based on 1 article reviews
e6 protein - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
recombinant viral hpv e6 protein cf  (R&D Systems)
N/A
The Recombinant Viral HPV E6 Protein from R D Systems powered by Boston Biochem is derived from E coli The Recombinant Viral HPV E6 Protein has been validated for the following applications Bioactivity
   Buy from Supplier

Image Search Results


a. HPV-16 therapeutic vaccine clinical trial design. Patients received vaccines targeting E6 and E7 proteins at Week 0, 4, and 8. PBMCs were collected pre-vaccination, at Week 10, and at Week 15 post-series completion. b. left, UMAP clustering of CD4+ T cells from PBMCs of HPV16+ patients with persistent precancerous lesions. right, HPV16-specific CD4+ T cells identified by SCT-dextramers. c. Highlighting of H1-H5 TCR clones among HPV16-specific CD4+ T cells. d. Expression of signature gene markers for defining phenotype clusters. Mean expression levels were normalized across groups. e. Engineering of primary CD4+ T cells with HPV-specific TCRs. CD4+ T cells were enriched from haplotype-matched PBMCs, endogenous TCRs were knocked out using CRISPR, and HPV TCRs were transduced via lentivirus. f. Validation of TCR specificity by tetramer binding (n=3) . g. Transduction efficiency of HPV-specific CD4 TCRs into primary CD4+ versus CD8+ T cells. h. Alanine scanning to identify key TCR recognition motifs. H2- and H5-TCR-transduced CD4+ T cells were cocultured with DR1+ K562 cells pulsed with alanine-substituted 9-mer core peptides (A1-A9) across 0.001 – 1 μM. IFNγ secretion was measured (OD 450 ). i. Cross-reactivity analysis against human self-antigens. H2- and H5-TCR-transduced T cells were co-cultured with LCLs pulsed with peptides identified from BLAST search and motif scans. H2 TCR used a single 1 µM dose; H5 TCR was dose titrated at 1, 2, and 10 µM. j. Alloreactivity screen. H2- and H5-TCR-transduced CD4+ T cells were tested against 41 LCL lines representing 92 distinct class II HLA alleles. DRB1*01:01-positive LCLs ( n=4 ) pulsed with E6 91-107 or E6 129-142 served as positive controls. Alloreactivity of H5 to HLA-DRB1*13:05-positive LCLs is marked with orange arrows. k. Confirmation of H2 TCR reactivity to naturally processed E6 antigen. DRB1*01:01+ LCL (GM17281B) was titrated with full-length E6 protein (0-10 μg/mL), co-cultured with H2-TCR-transduced CD4+ T cells, and evaluated for IFNγ secretion. A DRB1*01:01-LCL (GM12244A) served as a negative control.

Journal: bioRxiv

Article Title: Whole-Proteome Screening and Multi-Modal Profiling of Antigen-Specific CD4+ T Cells at Single-Cell Resolution

doi: 10.1101/2025.04.21.649828

Figure Lengend Snippet: a. HPV-16 therapeutic vaccine clinical trial design. Patients received vaccines targeting E6 and E7 proteins at Week 0, 4, and 8. PBMCs were collected pre-vaccination, at Week 10, and at Week 15 post-series completion. b. left, UMAP clustering of CD4+ T cells from PBMCs of HPV16+ patients with persistent precancerous lesions. right, HPV16-specific CD4+ T cells identified by SCT-dextramers. c. Highlighting of H1-H5 TCR clones among HPV16-specific CD4+ T cells. d. Expression of signature gene markers for defining phenotype clusters. Mean expression levels were normalized across groups. e. Engineering of primary CD4+ T cells with HPV-specific TCRs. CD4+ T cells were enriched from haplotype-matched PBMCs, endogenous TCRs were knocked out using CRISPR, and HPV TCRs were transduced via lentivirus. f. Validation of TCR specificity by tetramer binding (n=3) . g. Transduction efficiency of HPV-specific CD4 TCRs into primary CD4+ versus CD8+ T cells. h. Alanine scanning to identify key TCR recognition motifs. H2- and H5-TCR-transduced CD4+ T cells were cocultured with DR1+ K562 cells pulsed with alanine-substituted 9-mer core peptides (A1-A9) across 0.001 – 1 μM. IFNγ secretion was measured (OD 450 ). i. Cross-reactivity analysis against human self-antigens. H2- and H5-TCR-transduced T cells were co-cultured with LCLs pulsed with peptides identified from BLAST search and motif scans. H2 TCR used a single 1 µM dose; H5 TCR was dose titrated at 1, 2, and 10 µM. j. Alloreactivity screen. H2- and H5-TCR-transduced CD4+ T cells were tested against 41 LCL lines representing 92 distinct class II HLA alleles. DRB1*01:01-positive LCLs ( n=4 ) pulsed with E6 91-107 or E6 129-142 served as positive controls. Alloreactivity of H5 to HLA-DRB1*13:05-positive LCLs is marked with orange arrows. k. Confirmation of H2 TCR reactivity to naturally processed E6 antigen. DRB1*01:01+ LCL (GM17281B) was titrated with full-length E6 protein (0-10 μg/mL), co-cultured with H2-TCR-transduced CD4+ T cells, and evaluated for IFNγ secretion. A DRB1*01:01-LCL (GM12244A) served as a negative control.

Article Snippet: A DRB1*01:01+ LCL (GM17281B) was pulsed with E6 protein (Rndsystems, AP-120) at 10 μg/mL, 2 μg/mL, 1 μg/mL, and 0 μg/mL for 3 hours, and then co-cultured with H2-TCR-transduced CD4+ T cells overnight.

Techniques: Vaccines, Clone Assay, Expressing, CRISPR, Binding Assay, Transduction, Cell Culture, Negative Control